Skip to content

Nuvation Bio NUVB Non Cash Interest On Revenue Interest Financing Agreement

Non Cash Interest On Revenue Interest Financing Agreement at other companies

Cytokinetics logo
CytokineticsCYTK
$18.82M+33.4%
ImmunityBio, Inc. logo
ImmunityBio, Inc.IBRX
$8.32M-37.3%
Rhythm Pharmaceuticals, Inc. logo
Rhythm Pharmaceuticals, Inc.RYTM
$4.58M-15.4%
Novanta logo
NovantaNOVT
$368K+26.7%
Healthcare Realty Trust logo
Healthcare Realty TrustHR
$428K+140%
Cytokinetics logo
CytokineticsCYTK
$18.82M+33.7%

Other financials

Income statement

See full
Revenue$83.2M+2,599%
Gross profit$9.8M+1,340%
Operating income$3.9M+107%
Net income$5.4M+110%
EPS (diluted)$0.01+106%

Balance sheet

See full
Cash & equivalents$125.4M+161%
Total debt$57.2M+401%
Total equity$319.6M-23.8%
Total assets$610.2M+23.9%

Cash flow

See full
Operating cash flow$5.1M+112%
CapEx$48.0K-33.3%
Free cash flow$5.0M+112%

Valuation

See full
Market cap$2.25B+150%

Profitability

See full
Gross margin54.3%+39.5pp
Operating margin-105%-52.0pp
Net margin-102.1%-50.6pp
FCF margin-93.5%-45.2pp

Returns & leverage

See full
Return on equity-39.5%-15.8pp
Debt / equity0.2×+0.2×
Current ratio7.4×-1.6×

Where this comes from

Reported directly by Nuvation Bio in its filing.

Tagged under the XBRL concept nuvb:NonCashInterestOnRevenueInterestFinancingAgreement.

The official record: Nuvation Bio’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →

Ask your AI about Nuvation Bio's non cash interest on revenue interest financing agreement.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Nuvation Bio's non cash interest on revenue interest financing agreement?
Nuvation Bio (NUVB) reported non cash interest on revenue interest financing agreement of -$5.08M in Q1 2026.
What does non cash interest on revenue interest financing agreement mean?
Reflects the non-cash interest expense accrued related to revenue-based financing arrangements. This adjustment accounts for the difference between the effective interest recognized and the actual cash payments made to financing partners.